Authors
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to ClassificationNuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Latest:
Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab BiosimilarsPrerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.
Latest:
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRCFirst-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.
Latest:
Navigating Data Integrity for Generic Drug ApprovalsContinuous innovation is required in various technological aspects to effectively manage the challenges of vast clinical data.
Latest:
Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab MarketStephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.
Latest:
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar TreatmentDespite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest:
The Promise of Biosimilars Is Within Reach for Health SystemsA collaborative exercise with 16 health care organizations nets millions in savings.
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to ClassificationNuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and BeyondThe US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Latest:
A Promise Unfulfilled: The State of BiosimilarsFor biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.
Latest:
Integrating Biosimilars Into Retina and Neurology Practices Requires Careful PlanningSuccessfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.
Latest:
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug AccessChristopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Latest:
Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast CancerRyan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.
Latest:
The Underlying Economics of Unbranded BiologicsUnbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.
Latest:
Column: India Struggles to Meet International Biologics StandardsAn internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
Latest:
Resources for Patients and Providers on Adalimumab BiosimilarsExpert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
Opinion: Biosimilars Offer Savings and Access for US PatientsIn this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.
Latest:
Biosimilars and Women's Health: Realizing the PotentialThe potential and promise of biosimilars are there—it is up to all of us to bring it to reality so we can expand access to safe, effective, affordable drugs for women.
Latest:
Opinion: Support Health Equity and Access to Health Care With More Affordable Treatment OptionsChanges in federal and state policy can help liberate the savings potential in biosimilars and broaden investment in our health care system.
Latest:
Biosimilar Cases to Watch: Prolia/Xgeva and Denosumab CompetitorsThe denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation continues to shape the competitive landscape.
Latest:
Dr Chelsee Jensen Speaks on How Health Systems Can Build Confidence in BiosimilarsChelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains what health organizations and health systems can do to better manage and instill confidence in biosimilars.
Latest:
Pharmacists Play a Crucial Role in Adalimumab Biosimilars for Patient CareAdalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.
Latest:
Resources for Patients and Providers on Adalimumab BiosimilarsExpert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
Latest:
Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar SwitchHealth literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.
